Download Files:
Macitentan
$55 – $165
Products Details
Product Description
– Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].
Web ID
– HY-14184
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C19H20Br2N6O4S
References
– [1]Sen S, et al. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.
Life Sci. 2012 Apr 13.|[2]Kim SJ, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.
Transl Oncol. 2012 Feb;5(1):39-47.|[3]Bruderer S, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
AAPS J. 2012 Mar;14(1):68-78.|[4]Corallo C, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228.
CAS Number
– 441798-33-0
Molecular Weight
– 588.27
Compound Purity
– 99.95
SMILES
– BrC1=CN=C(OCCOC2=C(C3=CC=C(Br)C=C3)C(NS(NCCC)(=O)=O)=NC=N2)N=C1
Clinical Information
– Launched
Research Area
– Cardiovascular Disease; Endocrinology; Cancer
Solubility
– DMSO : ≥ 50 mg/mL
Target
– Apoptosis;Endothelin Receptor
Isoform
– ETA;ETB
Pathway
– Apoptosis;GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
